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There exists an urgent need for new target discovery to treat Alzheimer’s disease (AD); however, recent clinical trials based on anti-
Aβ and anti-inﬂammatory strategies have yielded disappointing results. To expedite new drug discovery, we propose reposition
targets which have been previously pursued by both industry and academia for indications other than AD. One such target
is the calcium-activated potassium channel KCa3.1 (KCNN4), which in the brain is primarily expressed in microglia and is
signiﬁcantly upregulated when microglia are activated. We here review the existing evidence supporting that KCa3.1 inhibition
could block microglial neurotoxicity without aﬀecting their neuroprotective phagocytosis activity and without being broadly
immunosuppressive. The anti-inﬂammatory and neuroprotective eﬀects of KCa3.1 blockade would be suitable for treating AD
as well as cerebrovascular and traumatic brain injuries, two well-known risk factors contributing to the dementia in AD patients
presenting with mixed pathologies. Importantly, the pharmacokinetics and pharmacodynamics of several KCa3.1 blockers are well
known, and a KCa3.1 blocker has been proven safe in clinical trials. It is therefore promising to reposition old or new KCa3.1
blockers for AD preclinical and clinical trials.
1. Repositioningan “Old,” Non-AD Speciﬁc
Target for AD Therapy
All currently FDA-approved drugs for Alzheimer’s disease
(AD),thethreeacetylcholinesteraseinhibitorsAricept,Raza-
dyne, and Exelon, and the N-methyl-D-aspartate receptor
antagonist, Namenda, only treat the symptoms of AD
and cannot hold its progression. There therefore exists an
urgent need for new target discovery to treat AD. The
main approaches for AD drug discovery tend to focus on
AD-speciﬁc molecular targets, such as those involved in
the generation and aggregation of amyloid-β protein (Aβ).
Several such targets have been investigated and have driven
developments of therapeutic reagents showing impressive
preclinical eﬃcacy. However, very few of these developments
have resulted in target validation in humans or successful
translation to disease-modifying therapies [1].
T h e s es e t b a c k sc o u l ds t i l lb eo v e r c o m e[ 2], but, in our
view, should prompt pursuit of alternative approaches to
target molecules that are not AD speciﬁc, which could
provide additional chance of success. There are two major
approaches under this category: either one could devise a
broadly neuroprotective compound that is useful for many
CNS indications, or one could “reposition” an existing
target which has been previously pursued by both industry
and academia for other indications and therefore is better
understood. The former approach makes sense because
it is increasingly obvious that AD is caused by multiple
converging insults related but not speciﬁc to AD rather
than by a single cascade pathway [3, 4]. This, in our view,
is perhaps one of the reasons for failures of clinical trials
targeting AD-speciﬁc pathways. We need to recall that the
overwhelmingly major risk factor for AD is aging, and
aging is certainly a multifactorial process. In addition, in2 International Journal of Alzheimer’s Disease
reality, “pure AD” is relatively uncommon; most demented
individuals show multiple pathologies including Lewy body
pathology, TDP-43 pathology, and cerebrovascular diseases
(CVDs), in addition to the traditional AD-type amyloid
plaques and neuroﬁbrillary tangles [5, 6]. In particular, the
combination of CVD and AD commonly called “mixed
dementia,” accounts for most dementia cases in community-
dwelling older persons [7]. Approximately 60 to 90% of
individuals with AD also have vascular brain pathologies
[8]. Drugs speciﬁcally targeting pure AD pathologies may
not address these common comorbidities, while broadly
neuroprotective compounds could perhaps better address
the downstream common pathways leading to synaptic
and neuronal dysfunction. As an example, recently the
Schubert group developed a drug screening procedure that is
based upon old age-associated pathologies without requiring
preselected molecular targets. The panel of screening assays
was able to identify compounds that protect neurons from
loss of trophic support, oxidative stress, aberrant energy
metabolism, and amyloid toxicity. They subsequently iden-
tiﬁed a lead compound that showed promising eﬀects in
enhancing the memory performance of a transgenic AD
mouse model [9]. Because the targets of this compound,
although unknown, are not restricted to the AD-related
amyloid toxicity pathway, this compound also facilitated
memoryinnormalrodents.Viewedasa“memoryenhancer,”
this compound is predicted to be useful in other CNS
indications aﬀecting memory.
Our own approach, being reviewed here, is to reposition
a target, KCa3.1, which has been pursued for both non-CNS
and CNS indications for years, for AD therapy. We have to
keep in mind that on average it currently takes at least 15
years and $1.5 billion to bring a drug for a major indication
like AD to market. As an example, for more than a decade,
remarkable eﬀorts and resources have been devoted to anti-
Aβ strategies based on the widely accepted amyloid cascade
hypothesis [10]. However, results from several clinical trials
are disappointing, for a multitude of reasons. In essence,
Golde et al. pointed out that none of the putative anti-
Aβ agents that have failed in pivotal phase 3 trials were
optimal or even optimized agents within their class of anti-
Aβ therapeutics [2]. They were hampered by low potency,
poor brain penetration, and signiﬁcant mechanism-based
toxicity (such as from the nonselective action of γ-secretase
inhibitors to block physiological functions), illustrating the
practical diﬃculties of translating a brand new target to
a new clinically useful drug. In addition, toxicity or poor
tolerance during clinical trials is a common reason leading
to failure of a new compound. It is therefore advantageous
to reposition known targets, for which a wealth of pharma-
cological knowledge has been accumulated, and safety has
been demonstrated in clinical trials. For these old targets,
there typically exist useful pharmacological tool compounds
thatcanbequicklyresynthesized,evaluatedinanimalmodels
to obtain proof-of-concept, and then optimized for speciﬁc
properties such as brain penetration. This approach should
expedite new drug development which is currently urgently
needed for AD.
2. Three Criteriafor Developing a
“Pathway-Selective”Inhibitor of
Microglial Activation for
Anti-Inﬂammatory Therapy
Neuroinﬂammation and associated neuronal dysfunction
mediated by activated microglia play an important role
in the pathogenesis of AD [14]. Microglia, the resident
macrophages and major mediator of neuroinﬂammation
in the brain, can be activated by a variety of pathologic
stimuliincludingtheamyloidaggregatesformedbyamyloid-
β protein (Aβ)[ 15–17]. Although microglia were initially
noted to be abundantly present around amyloid plaques
[18] and thought to be involved in plaque formation,
recentpositronemissiontomographystudiesofpatientswith
mild cognitive impairment (MCI) concluded that microglia
activation occurs even before plaque and tangle formation
[19] and is correlated with early cognitive deﬁcits [20].
Although the exact stimuli that induce pathologic activation
of microglia await further study, our recent results suggest
that soluble Aβ oligomers (AβOs), the small and early-
stage amyloid aggregates could be a potent stimulus [17]. A
reasonable assumption is that multiple stimuli converge to
cause microglial dysfunction and aberrant activation, thus
aggravating microglia-mediated neurotoxicity and reducing
theirneuroprotectivecapacity.Indeed,avarietyoflifeevents,
such as trauma, infection, stroke, metabolic disorders, and
network hyperexcitability (epileptic seizures), have been
implicated in contributing to the development of AD.
Notably, all these conditions invariably activate microglia.
Activated microglia release cytotoxic substances and proin-
ﬂammatory cytokines to cause neuronal damage and age-
associated microglial dysfunction [17, 21–23]. Above all,
aging is perhaps the major risk and a prerequisite for “patho-
logicactivation”thatpreventsmicrogliafromperformingthe
intended neuroprotective and repair functions [24, 25].
Irrespective of the events causing neuroinﬂammation
in AD, curbing the harmful proinﬂammatory response of
microglia activation is a reasonable approach toward pre-
vention or therapy of AD. However, despite abundant pre-
clinical evidence of their beneﬁt, various anti-inﬂammatory
approaches have not proven successful in clinical trials
for a multitude of reasons. The most widely tested anti-
inﬂammatory agents are the nonsteroidal anti-inﬂammatory
drugs (NSAIDs). NSAIDs show multiple beneﬁcial eﬀects on
preclinical cell culture and animal models of AD, although
the exact molecular targets mediating these eﬀects are not
known. Unfortunately, results from several clinical trials
are disappointing [26], partly due to inadequate CNS drug
penetration ofexisting NSAIDs,suboptimal doses,unknown
molecular targets (therefore unknown pharmacodynamics),
and toxicities. For example, a recent large-scale AD preven-
tion trial with NSAIDs, including naproxen and celecoxib,
was stopped early because of drug safety concerns. Despite
this, these setbacks should prompt investigations to develop
novel anti-inﬂammatory agents with known speciﬁc targets,
satisfactory CNS penetrance, and low toxicities.
We also have to consider that microglial activation can be
neuroprotective through the release of neurotrophic factorsInternational Journal of Alzheimer’s Disease 3
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Figure 1: KCa3.1 regulates microglial activation by modulating Ca2+ inﬂux. AβO initiates an increase of intracellular Ca2+ either directly by
forming a Ca2+-permeable membrane pore (AβO-Ca2+ pore) [11, 12] or indirectly through interaction with a receptor (tentatively termed
AβO-R). Intracellular Ca2+ activates KCa3.1 to induce K+ eﬄux. The resulting hyperpolarisation provides the driving force for Ca2+ entry
through store-operated inward-rectiﬁer calcium channels like CRAC, thus sustaining the Ca2+ signal necessary for selective Ca2+ activated
pathways. One example illustrated here is iNOS activation and nitric oxide (NO) production to cause microglia-mediated neurotoxicity.
and by phagocytosing Aβ and debris from degenerated
neurons [14, 23]. Any anti-inﬂammatory therapies for
AD should take these dichotomous microglial functions
into consideration [23]. This constitutes our criteria no.1
for microglia-targeted therapy in AD: the therapy should
maintain microglial ability to migrate and clear Aβ, while
inhibiting their release of neurotoxic mediators. Recent
evidence suggests that this could be achieved by control-
ling the activities of speciﬁc pathways that can modulate
certain aspects of microglia activation. Proposed approaches
include modulation of the peroxisome proliferator-activated
receptor-γ (PPAR-γ)[ 14] and the E prostanoid receptor
subtype 2 [27]. Evidence obtained from our laboratory
and from other groups strongly suggests blockade of the
calcium-activated K+ channel KCa3.1 as another promising
approach that could curb inﬂammatory brain pathologies
while preserving microglial migration and phagocytosis [13,
17, 28–30].
Twoadditionalcriteriaforananti-inﬂammatorydrugfor
ADtherapyare:criteriano.2,itshouldberelativelyspeciﬁcto
microglia to avoid adverse neuronal eﬀects and criteria no.3,
it should not be broadly immunosuppressive. We will review
evidence supporting that KCa3.1 is a suitable therapeutic
target for AD using the above three criteria.
3.KCa3.1 asaMicroglia-Selective
Target in CNS
K+ channels are encoded by a super-family of 78 genes [31]
and are involved in diverse physiological and pathological
processes [32]. K+ channels accordingly already serve as drug
targets for cardiac arrhythmia, type-2 diabetes, and epilepsy
and have been proposed as potential targets for various
neurological diseases such as multiple sclerosis, Parkinson’s
disease, stroke, pain, schizophrenia, and migraine. Two K+
channels, the calcium-activated KCa3.1 (also known as IK1,
SK4 or KCNN4) and the voltage-gated Kv1.3, play important
roles in microglia activation by modulating Ca2+ signaling
and membrane potential. Similar to T cells, where their
r o l e sh a v eb e e ns t u d i e di nm u c hm o r ed e t a i l[ 33], K+
eﬄux through microglial KCa3.1 and Kv1.3 helps maintain
a negative membrane potential for Ca2+ inﬂux through the
store-operated inward rectiﬁer calcium channel CRAC (Ca2+
release activated Ca2+ channel) (Figure 1). However, the two
K+ channels appear to be diﬀerentially expressed following
immune cell activation and diﬀerentially modulate cytokine
production and cellular proliferation in diﬀerent T and B
cell subsets. While Kv1.3 is primarily important in CCR7−
eﬀector memory T cells and class-switched IgD−CD27+ B
cells, CCR7+ Tc e l l sa n dI g D + B cells rely on KCa3.1 for
part of their calcium-signaling and activation events [34–
37]. In microglia, KCa3.1-mediated control of Ca2+ entry
has been shown to be involved in oxidative burst, nitric
oxide production, and microglia-mediated neuronal killing,
including that induced by Aβ oligomer (AβO) [17, 28, 38,
39].
Although no human diseases involving KCa3.1 muta-
tions have been described so far, KCa3.1 constitutes a
very attractive and (in some cases) relatively well-validated
drug target for diseases or conditions ranging from sickle
cell disease, restenosis, and atherosclerosis to asthma and
traumatic brain injury (see [40] for a recent review). KCa3.1
channels are widely expressed throughout the body and
primarily found in hematopoietic-derived cells including
macrophages/microglia. A signiﬁcant advantage of KCa3.1
channels as a therapeutic target for CNS indications is that
expression seems to be restricted to hematopoietic-derived
cells and peripheral tissues such as secretory epithelial,
ﬁbroblasts, and proliferating neointimal smooth muscle cells
[40], but the channels have been found to be absent from
excitable tissues such as neurons and cardiomyocytes [41–
43]. KCa3.1 channels appear also not expressed in astrocytes.
However, evidence shown in a recent article by Bouhy et al.
suggests expression of KCa3.1 in reactive astrocytes in the
spinal cord of a mouse spinal cord injury model, although
only one anti-KCa3.1 antibody was used in immunohisto-
chemistry [30]. We feel that this is clearly not the case for
the forebrain, based on previously published gene expression
data [41, 43]. Our own experiments using several polyclonal4 International Journal of Alzheimer’s Disease
Table 1
Structure Pharmacokinetics/pharmacodynamics/safety Development status
N
N
Cl
Clotrimazole
(1) KCa3.1 IC50 70–250nM
(2) Acute inhibition and chronic induction of cytochrome P450-dependent
enzymes
(3)Liver toxic
Topical antifungal generally
regarded as too toxic for
internal use
N
N
Cl
TRAM-34
(1) KCa3.1 IC50 20nM
(2) No toxicity in 28-day and 6-month tox studies in rodents
(3) t1/2= 2 hours (rats, primates)
(4) Cbrain/Cplasma1.2
(5) Not orally available
Patented by the University
of California WO 01/49663
(2001)
F
F
O
NH2
ICA-17043 (senicapoc)
(1) KCa3.1 IC50 11nM
(2) Orally available in humans
(3) t1/2= 12.8 days (humans)
(4) IND enabling preclinical toxicity studies in two species
Failed to reduce number of
sickling crisis in Phase-3
clinical trial for sickle cell
anemia after having been
found safe and eﬀective in
Phase-1 and Phase-2
Developed at Icagen
O
O
Cl
H3COOC
CF3 Cyclohexadiene lactone
(1) KCa3.1 IC50 8nM
(2) Cbrain/Cplasma10
(3) Used for traumatic brain injury studies [13]
Compounds seem to have
been abandoned when
Bayer pulled out of stroke
research
Patented by Bayer AG
Germany, DE-9619612645
(1997)
and monoclonal anti-KCa3.1 antibodies to stain sections
from models of AD (unpublished results) and stroke [29]
show that KCa3.1 is substantially upregulated in activated
microglia, but not in astrocytes. We therefore feel that we
can perhaps conclude that the major parenchymal cells in
the cerebrum in which KCa3.1 channels play a signiﬁcant
role are microglia, and in some pathological conditions,
invading macrophages. Therefore, it is reasonable to assume
that a CNS-permeating KCa3.1 blocker would have relatively
selective actions on microglia and would avoid adversely
aﬀecting neuronal functions.
4.KCa3.1 Blockers AreNeuroprotective
Recognizing the important role of KCa3.1 in regulating
immune cell functions, Wulﬀ et al. synthesized a speciﬁc
KCa3.1 blocker called TRAM-34 using as a template the
antimycotic clotrimazole, which is a potent but poorly
tolerated KCa3.1 inhibitor [44]. TRAM-34 (IC5020nM)
is currently the most widely used pharmacological tool
compound for studying the pathophysiology of KCa3.1
because of its high selectivity over other K+ channels and
its availability to academic researchers. Table 1 shows the
structures of TRAM-34 and several other KCa3.1 blockers
developed by pharmaceutical companies and summarizes
pharmacokinetic, safety, and development information. For
more extensive reviews on KCa3.1 pharmacology, interested
readers are referred to two review articles [40, 45].
TRAM-34 has been tested in various animal models,
including optic nerve transaction [28], middle cerebral
artery occlusion [29], traumatic brain injury [13]a n d
restenosis [46] in rats; traumatic spinal cord injury [30],
atherosclerosis [47], and inﬂammatory bowel disease [37]
in mice; and angioplasty in pigs [48]. In particular, the
following in vivo observations taken together provide strong
evidencethatKCa3.1inhibitorscancurbbraininﬂammation
and provide neuroprotection.
(1) Our own group recently demonstrated that TRAM-
34 inhibits AβO-induced microglia activation and
microglia-mediated neuronal toxicity [17].
(2) Our group further showed that TRAM-34 inhibits
microglia activation and reduces infarct area and
neurological deﬁcit scores in a rat model of ischemic
stroke even if treatment is commenced 12h after
reperfusion [29].
(3) The Schlichter group showed that TRAM-34 reduces
retinal ganglion cell degeneration after optic nerve
transection in rats [28]. Interestingly, KCa3.1 block-
ade did not prevent microglia from aligning with
damaged axons or from phagocytosing damaged
neurons, but increased the number of surviving
retinal ganglion cells presumably by reducing the
production and/or secretion of neurotoxic molecules
intheretina[28].ThiscouldpossiblybeexplainedbyInternational Journal of Alzheimer’s Disease 5
the observation that the Ca2+ inﬂux during phagocy-
tosis appears to be mediated through reverse mode
Na+/Ca2+ exchange [49] and not through KCa3.1-
regulated CRAC channels, supporting the “pathway-
selective” nature of KCa3.1 inhibition.
(4) The David group showed that TRAM-34 reduces the
secondary damage and improves locomotor function
in a mouse model of spinal cord injury in a dose-
dependent manner [30].
(5) ScientistsatBayerdemonstratedthattwostructurally
diﬀerent KCa3.1 inhibitors, a triarylmethane and a
cyclohexadiene(Table 1),reducedinfarctvolumeand
brain edema following traumatic brain injury caused
by acute subdural haematoma in rats [13].
(6) Scientists at Schering resynthesized TRAM-34 and
showed that it treats MOG-induced experimental
autoimmune encephalomyelitis in mice by reducing
the production of the inﬂammatory cytokines INF-γ
and TNF-α in the brain and spinal cord [50].
5.TargetingKCa3.1 CouldAmeliorate
AβO-InducedNeuronal Damage
AβOs, the small soluble and diﬀusible aggregates of Aβ
peptides, were initially considered transient or metastable
intermediates in ﬁbril formation [51]. However, some of
them may not be obligate intermediates in the ﬁbril forma-
tion pathway and can be stable [52, 53]. Importantly, recent
in vitro and in vivo studies have revealed that the buildup of
soluble AβO may be an early and central event in the patho-
g e n e s i so fA D[ 54–57]. The strong and rapidly disruptive
eﬀect of AβO on synaptic plasticity and neuronal integrity
is hypothesized to cause memory problems in AD and is
generally attributed to their direct neuro- or synaptotoxicity
[10]. However, one plausible but less studied possibility is
that AβO activates microglia and causes indirect, microglia-
mediated neuro- and synaptotoxicity. Recently we found
that AβO, either assembled in vitro from synthetic Aβ1-
42 peptide or isolated from AD brains, is a highly potent
activatorofmicroglia[17].Althoughthemechanismmediat-
ing AβO-induced microglia activation and the exact pattern
of activation are still under investigation, a particularly
interesting observation is that this mode of microglia activa-
tion and related neurotoxicity are dependent on microglial
KCa3.1. We found that TRAM-34 blocked AβO-induced
microglia proliferation, p38MAPK phosphorylation, NFκB
activation, and nitric oxide generation. We further showed
that the neurotoxic eﬀects of low concentrations of AβO
(10–50nM) applied to mixed microglia-neuron cultures
or organotypic hippocampal slices were almost completely
blocked by cotreatment with TRAM-34, another microglial
activation inhibitor doxycycline, and inhibitors of iNOS.
This set of results suggests that AβO, although generally
considered a neurotoxin, may more potently cause indirect
neuronal damage by activating microglia in AD. Consistent
with this notion, a previous study showed that the inhibition
of NMDA receptor-dependent long-term potentiation by
soluble Aβ can be prevented by minocycline, a microglia
activation inhibitor in the same class as doxycycline, and
iNOS inhibition to reduce nitric oxide production from
microglia [58]. Taken together, these results suggest that
KCa3.1 blockers could potentially also inhibit microglial
neurotoxicity and thus preserve memory in AD.
6.TargetingKCa3.1 CouldAlso
EffectivelyAddress Cerebrovascular
andTraumaticComorbidities inAD
As discussed above, cerebrovascular insults and traumatic
brain injuries are signiﬁcant comorbidities in AD. In
addition to clinically apparent strokes, carotid, vertebral,
and intracranial vascular stenosis can cause chronic cere-
bral hypoperfusion, microinfarcts, and lacunar infarcts,
contributing to dementia. These vascular and traumatic
pathologies cannot possibly be addressed by AD-speciﬁc
therapies, such as antiamyloid drugs or vaccines. The well-
documented beneﬁcial eﬀects of KCa3.1 blockers in models
of ischemic stroke [29], traumatic brain injury [13], and
atherosclerosis [47], which primarily seem to be mediated
through inhibition of detrimental microglia/macrophage
function, considerably add to KCa3.1
 sa t t r a c t i v e n e s sa sa
novel target for treating the dominant group of AD patients
presenting with both degenerative and vascular pathologies.
KCa3.1 is further expressed in dediﬀerentiated, proliferative
vascularsmoothmusclescells,which,asK¨ ohleretal.showed,
switch from their normal KCa1.1 (BK) channel expression to
KCa3.1expressionfollowingballooncatheterinjury.Inkeep-
ing with a role of KCa3.1 in driving aberrant smooth muscle
cell proliferation, TRAM-34 prevents vascular restenosis in a
ratmodel[46]. These ﬁndings were more recently conﬁrmed
by a study in which coating of TRAM-34 onto balloon
catheters signiﬁcantly reduced restenosis in pigs, which very
closely resemble humans with respect to postangioplasty
restenosis [48]. A similar increase in KCa3.1 expression
was found in coronary vessels from patients with coronary
artery disease and in aortas from ApoE−/− mice, suggesting
that KCa3.1 is involved in atherogenesis. KCa3.1 blockade
with TRAM-34 prevented atherosclerosis development in
ApoE−/− mice by reducing smooth muscle cell proliferation
and macrophage inﬁltration into atherosclerotic plaques
[47]. Furthermore, TRAM-34 administration reduced the
inﬂammatory neurotoxicity and infarct areas in the wake
of ischemic stroke, even when the ﬁrst dose was applied
at 12 hours after reperfusion. This was accompanied by a
dose-dependent improvement in neurological deﬁcit score,
a reduction in the number of ED1+ activated microglia and
an increase in NeuN+ surviving neurons [29].
7.KCa3.1 BlockersAreMild
ImmunosuppressantsandAre
Relatively Safe
The promise of KCa3.1 as a therapeutic target for AD
is further strengthened by the observations that KCa3.1
blockers are very mild immunosuppressants that do not6 International Journal of Alzheimer’s Disease
reduce the ability of rodents to clear viral infections like
ﬂu [47]. In addition, genetic or pharmacological blockade
of KCa3.1 seems relatively safe and well tolerated. Two
independently generated KCa3.1−/− mice were both viable,
of normal appearance, produced normal litter sizes, did
not show any gross abnormalities in any of their major
organs, and exhibited rather mild phenotypes: impaired
v o l u m er e g u l a t i o ni ne r y t h r o c y t e sa n dl y m p h o c y t e s[ 59],
a reduced EDHF (endothelium derived hyperpolarizing
factor) response together with a mild ∼7mmHg increase
in blood pressure [60], and subtle erythrocyte macrocytosis
and progressive splenomegaly [61]. A 28-day toxicity study
with TRAM-34 in mice resulted in no observable changes
in blood chemistry, hematology or necropsy of any of the
major organs [47]. A subsequent 6-month toxicity study
with TRAM-34 in rats also did not ﬁnd any changes in the
same parameters and also did not report any increases in
susceptibility to viral or bacterial infections [29]. Senicapoc,
a KCa3.1 blocker structurally similar to TRAM-34 (see
Table 1), was safe and well tolerate, in a Phase-1 clinical
trial in healthy volunteers [62] and was afterwards found
to signiﬁcantly reduce hemolysis and increase hemoglobin
levels in a 12-week, multicenter, randomized double-blind
Phase-2 study in sickle cell disease patients [63]. However, in
a subsequent Phase-3 study, which was designed to compare
the rate of acute vasoocclusive pain crisis occurring in
sickle cell disease patients, Senicapoc failed to reduce this
desired clinical endpoints despite again reducing hemolysis
and increasing hemoglobin levels and not inducing any
signiﬁcant adverse events (see [40]f o ram o r ee x t e n s i v e
discussion of the clinical experiences with KCa3.1 blockers).
8. Conclusion: MicroglialKCa3.1 Is
a Promising Target for AD
Concluding the above discussion, we here propose that
microglial KCa3.1 is a promising therapeutic target for AD
because KCa3.1 blockade comes close to fulﬁlling three cri-
teria we set for anti-inﬂammatory therapy. Using the speciﬁc
KCa3.1 inhibitor TRAM-34 as a pharmacological tool com-
pound, proof-of-concept studies have shown that KCa3.1
inhibition can reduce AβO-induced microglial neurotoxicity
andprotectneuronsinothernon-Aβneuronalinjurymodels
by reducing the production of neurotoxic proinﬂammatory
mediators while preserving the neuroprotective functions
of microglia, such as migration and phagocytosis. This
“pathway-selectivity” is likely due to the ability of KCa3.1 to
“ﬁne-tune” the pattern of microglial activation by selectively
regulating various Ca2+-activated signaling pathways. Due to
its demonstrated eﬀects on models of CVD and traumatic
brain injuries, two well-known risk factors for AD, KCa3.1
inhibition could oﬀer additional therapeutic beneﬁts for
mixed pathologies commonly seen in AD patients. KCa3.1
blockade by either pharmacological inhibition or genetic
knockout only resulted in minimal immunosuppression.
Importantly,aKCa3.1blockerhasbeenprovensafeinclinical
trials. Therefore, it is promising to either directly reposition
existing KCa3.1 blockers for AD preclinical proof-of-concept
studies and subsequent clinical trials and/or make eﬀorts to
optimize existing or newly-discovered compounds for oral
availability and brain penetration in order to expedite drug
development for AD.
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